145 related articles for article (PubMed ID: 38453187)
1. Comparison of prior authorization across insurers: cross sectional evidence from Medicare Advantage.
Gupta R; Fein J; Newhouse JP; Schwartz AL
BMJ; 2024 Mar; 384():e077797. PubMed ID: 38453187
[TBL] [Abstract][Full Text] [Related]
2. Measuring the Scope of Prior Authorization Policies: Applying Private Insurer Rules to Medicare Part B.
Schwartz AL; Brennan TA; Verbrugge DJ; Newhouse JP
JAMA Health Forum; 2021 May; 2(5):e210859. PubMed ID: 35977311
[TBL] [Abstract][Full Text] [Related]
3. Medicare Advantage coverage restrictions for the costliest physician-administered drugs.
Anderson KE; Alexander GC; Ma C; Dy SM; Sen AP
Am J Manag Care; 2022 Jul; 28(7):e255-e262. PubMed ID: 35852888
[TBL] [Abstract][Full Text] [Related]
4. Health Care Utilization and Spending in Medicare Advantage vs Traditional Medicare: A Difference-in-Differences Analysis.
Schwartz AL; Zlaoui K; Foreman RP; Brennan TA; Newhouse JP
JAMA Health Forum; 2021 Dec; 2(12):e214001. PubMed ID: 35977297
[TBL] [Abstract][Full Text] [Related]
5. Concentration of Physician Services Across Insurers and Effects on Quality: Early Evidence From Medicare Advantage.
Welch WP; Sen AP; Bindman AB
Med Care; 2019 Oct; 57(10):795-800. PubMed ID: 31415344
[TBL] [Abstract][Full Text] [Related]
6. Prescription Drug Coverage for Treatment of Low Back Pain Among US Medicaid, Medicare Advantage, and Commercial Insurers.
Lin DH; Jones CM; Compton WM; Heyward J; Losby JL; Murimi IB; Baldwin GT; Ballreich JM; Thomas DA; Bicket M; Porter L; Tierce JC; Alexander GC
JAMA Netw Open; 2018 Jun; 1(2):e180235. PubMed ID: 30646077
[TBL] [Abstract][Full Text] [Related]
7. Coverage Denials: Government And Private Insurer Policies For Medical Necessity In Medicare.
Schwartz AL; Chen Y; Jagmin CL; Verbrugge DJ; Brennan TA; Groeneveld PW; Newhouse JP
Health Aff (Millwood); 2022 Jan; 41(1):120-128. PubMed ID: 34982629
[TBL] [Abstract][Full Text] [Related]
8. Association Between a Bundled Payment Program for Lower Extremity Joint Replacement and Patient Outcomes Among Medicare Advantage Beneficiaries.
Sutherland A; Boudreau E; Bowe A; Huang Q; Liao JM; Flagg M; Cousins D; Antol DD; Shrank WH; Powers BW; Navathe AS
JAMA Health Forum; 2023 Jun; 4(6):e231495. PubMed ID: 37355996
[TBL] [Abstract][Full Text] [Related]
9. Geographical Variation in Health Spending Across the US Among Privately Insured Individuals and Enrollees in Medicaid and Medicare.
Cooper Z; Stiegman O; Ndumele CD; Staiger B; Skinner J
JAMA Netw Open; 2022 Jul; 5(7):e2222138. PubMed ID: 35857326
[TBL] [Abstract][Full Text] [Related]
10. Assessment of Out-of-Pocket Spending for COVID-19 Hospitalizations in the US in 2020.
Chua KP; Conti RM; Becker NV
JAMA Netw Open; 2021 Oct; 4(10):e2129894. PubMed ID: 34661662
[TBL] [Abstract][Full Text] [Related]
11. Coverage of Nonpharmacologic Treatments for Low Back Pain Among US Public and Private Insurers.
Heyward J; Jones CM; Compton WM; Lin DH; Losby JL; Murimi IB; Baldwin GT; Ballreich JM; Thomas DA; Bicket MC; Porter L; Tierce JC; Alexander GC
JAMA Netw Open; 2018 Oct; 1(6):e183044. PubMed ID: 30646222
[TBL] [Abstract][Full Text] [Related]
12. Removal of prior authorization for medication-assisted treatment: impact on opioid use and policy implications in a Medicare Advantage population.
Ferries E; Racsa P; Bizzell B; Rhodes C; Suehs B
J Manag Care Spec Pharm; 2021 May; 27(5):596-606. PubMed ID: 33908274
[No Abstract] [Full Text] [Related]
13. Prescription Drug Spending in Fee-for-Service Medicare, 2008-2019.
Dusetzina SB; Huskamp HA; Qin X; Keating NL
JAMA; 2022 Oct; 328(15):1515-1522. PubMed ID: 36255428
[TBL] [Abstract][Full Text] [Related]
14. Trends in Medicare Advantage participation among commercial insurers.
Marr J; Meiselbach MK; Polsky D
Am J Manag Care; 2023 Oct; 29(10):e317-e319. PubMed ID: 37870553
[TBL] [Abstract][Full Text] [Related]
15. Implementation of Medicare Part D and nondrug medical spending for elderly adults with limited prior drug coverage.
McWilliams JM; Zaslavsky AM; Huskamp HA
JAMA; 2011 Jul; 306(4):402-9. PubMed ID: 21791689
[TBL] [Abstract][Full Text] [Related]
16. Prior Authorization, Copayments, and Utilization of Sacubitril/Valsartan in Medicare and Commercial Plans in Patients With Heart Failure With Reduced Ejection Fraction.
Ozaki AF; Krumholz HM; Mody FV; Tran TT; Le QT; Yokota M; Jackevicius CA
Circ Cardiovasc Qual Outcomes; 2021 Sep; 14(9):e007665. PubMed ID: 34465124
[TBL] [Abstract][Full Text] [Related]
17. Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs.
Hwang TJ; Jain N; Lauffenburger JC; Vokinger KN; Kesselheim AS
JAMA Intern Med; 2019 Mar; 179(3):374-380. PubMed ID: 30640379
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Spending Differences Between Beneficiaries in Medicare Advantage and the Medicare Shared Savings Program.
Parikh RB; Emanuel EJ; Brensinger CM; Boyle CW; Price-Haywood EG; Burton JH; Heltz SB; Navathe AS
JAMA Netw Open; 2022 Aug; 5(8):e2228529. PubMed ID: 35997977
[TBL] [Abstract][Full Text] [Related]
19. Coverage and Prior Authorization Policies for Medications for Opioid Use Disorder in Medicaid Managed Care.
Abraham AJ; Andrews CM; Harris SJ; Westlake MM; Grogan CM
JAMA Health Forum; 2022 Nov; 3(11):e224001. PubMed ID: 36331441
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Out-of-Pocket Spending on Ultra-Expensive Drugs in Medicare Part D vs Commercial Insurance.
DiStefano MJ; Kang SY; Parasrampuria S; Anderson GF
JAMA Health Forum; 2023 May; 4(5):e231090. PubMed ID: 37234016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
